Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives $131.25 Average Price Target from Analysts

Shares of Spruce Biosciences, Inc. (NASDAQ:SPRB) have been assigned a consensus rating of “Reduce” from the seven ratings firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and six have assigned a hold rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $131.25.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Spruce Biosciences in a research report on Saturday, September 27th.

Spruce Biosciences Trading Down 7.6%

Spruce Biosciences stock opened at $7.95 on Friday. The stock has a 50 day moving average of $8.74 and a two-hundred day moving average of $9.66. Spruce Biosciences has a twelve month low of $4.28 and a twelve month high of $45.60. The stock has a market capitalization of $4.45 million, a price-to-earnings ratio of -0.09 and a beta of 2.47.

Spruce Biosciences Company Profile

Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.